Skip to content

Salt and HMB Study

The Roles of HMB and Sodium in Blood Pressure Regulation and Gut Microbiome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05515900
Enrollment
80
Registered
2022-08-25
Start date
2021-10-01
Completion date
2024-09-30
Last updated
2022-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Brief summary

Hypertension affects one-third of adults in the US. High salt diet is a key risk factor for elevated blood pressure (BP). The associations of gut microbiome with high salt diet and hypertension have been established in both animal and human studies. However, the underlying biological mechanisms linking sodium to BP elevation and gut microbiome alteration are not clear. Increasing evidence supports a pivotal role of leucine metabolism in hypertension. Leucine is initially catalyzed by the branched-chain amino acid aminotransferase enzyme (BCAT), producing α-ketoisocaproate (α-KIC), which can be further metabolized to β-hydroxy-β-methylbutyrate (HMB). Leucine/α-KIC/HMB metabolism pathway shows a promising involvement in the relationships among salt, gut microbiome, and elevated BP. Preliminary studies show that dietary sodium reduction increases circulating HMB, which is further associated with reduced BP, and that HMB treatment decreases Firmicutes/Bacteroidetes ratio, and increases α-diversity and gut microbiota-derived short-chain fatty acids (SCFAs). However, the leucine/α-KIC/HMB metabolism pathway has never been targeted in human studies. To establish causality, I propose a double-blind, two-stage randomized, placebo-controlled trial of sodium and HMB supplements for the following specific aims: Aim 1 will determine the effect of sodium supplement on leucine/α-KIC/HMB metabolism pathway. Aim 2 will determine the effect of HMB supplement on office BP and 24-hour ambulatory BP (Aim 2a), and α- and β-diversities and Firmicutes/Bacteroidetes ratio (Aim 2b). Secondary Aim will test the hypothesis that HMB supplement could partially block the detrimental effects of sodium intake on BP and gut microbiota. The proposed project would help to uncover the role of leucine/α-KIC/HMB metabolism pathway in salt-induced hypertension and the alteration in gut microbiome. Most importantly, the project will provide the training opportunities for me as a junior faculty, to study the new area of gut microbiome, acquire new experience and skills to conduct human trials. In addition, this project will generate rich preliminary data on the role of leucine/α-KIC/HMB metabolism pathway in salt-induced BP elevation, and test the feasibility for developing future NIH R01 project.

Interventions

DIETARY_SUPPLEMENTSodium

Daily sodium supplementation of 2000 mg.

DIETARY_SUPPLEMENTHMB

Daily HMB supplementation of 3 g.

OTHERPlacebo

Placebo pills that will be identical to sodium or HMB supplementations

Sponsors

American Heart Association
CollaboratorOTHER
Augusta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* normotensive \[SBP\<140 mmHg and diastolic BP (DBP)\<90 mmHg\]; * self-identified black or white; c. aged from 18 to 65 years.

Exclusion criteria

* taking medication that would affect BP or gut microbiome; * being pregnant; * with health conditions that would compromise sodium handling.

Design outcomes

Primary

MeasureTime frameDescription
Leucine/α-KIC/HMB metabolism4 weeksChanges in blood levels of metabolites leucine, α-KIC, and HMB from baseline to week 4.
Blood pressure4 weeksChanges in systolic and diastolic blood pressure from week 5 to week 8.
Gut microbiome4 weeksChanges in the composition of gut microbiome from week 5 to week 8.

Countries

United States

Contacts

Primary ContactLi Chen, PhD
lichen1@augusta.edu7067211764

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026